Vimarsana
Biggest News Aggregation in the World

Page 37 - Registration Statements News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Registration Statements. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Registration Statements Today - Breaking & Trending Today

CreditRiskMonitor.com, Inc.: CreditRiskMonitor Announces 2021 Results - Vimarsana News

CreditRiskMonitor.com, Inc.: CreditRiskMonitor Announces 2021 Results

VALLEY COTTAGE, NY / ACCESSWIRE / March 25, 2022 / CreditRiskMonitor (OTCQX:CRMZ) reported that operating revenues for the year ended December 31, 2021 increased to approximately $17 million up 8.5% from

Orphazyme A/S has filed for voluntary delisting of ADSs - Vimarsana News

Orphazyme A/S has filed for voluntary delisting of ADSs

21.03.2022 - Orphazyme A/SCompany announcementNo. 12/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, March 21, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces ...

GEE Group Revenue Up 24% in Announced First Quarter Results - Vimarsana News

GEE Group Revenue Up 24% in Announced First Quarter Results

14.02.2022 - GAAP Net Income $16.7 million; Diluted EPS $.14; Adjusted EBITDA $3.9 millionJACKSONVILLE, FL / ACCESSWIRE / February 14, 2022 / GEE Group Inc. (NYSE American:JOB) ('the Company' or 'GEE Group'), a provider of professional staffing services and ...

Purple Biotech Issues Letter to Shareholders - Vimarsana News

Purple Biotech Issues Letter to Shareholders

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Purple Biotech Issues Letter to Shareholders - Vimarsana News

Purple Biotech Issues Letter to Shareholders

REHOVOT, Israel, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor

Source: kulr8.com